新辅助化疗对大肠癌患者CD44v6,p27蛋白表达与预后的影响  

Influence of new neoadjuvant chemotherapy on the prognosis and the protein expression of CD44v6 and p27 in patients with colorectal cancinoma

作　　者：孙秀梅[1] 高峰[2] 李贵新[1] 刘康[1] 

机构地区：[1]潍坊医学院附属医院肿瘤科 [2]潍坊市人民医院,潍坊261031

出　　处：《中国新药杂志》2011年第17期1695-1698,共4页Chinese Journal of New Drugs

摘　　要：目的:探讨新辅助化疗对大肠癌患者CD44v6,p27蛋白表达与预后的影响。方法:我院大肠癌患者78例,根据临床分期分为A组(分期为Ⅰ,ⅡA期,39例)和B组(分期为ⅡB,Ⅲ,Ⅳ期,39例),用免疫组化的方法测定2组大肠癌患者新辅助化疗前后癌组织中CD44v6,p27的表达,并参照不良事件常用术语评定标准3.0版(CTCAE3)对新辅助化疗法治疗大肠癌患者引起的不良反应进行评价。结果:A组患者新辅助化疗前后直肠癌组织中CD44v6,p27的表达率差异无统计学意义;B组患者新辅助化疗前直肠癌组织中CD44v66和p27蛋白表达阳性细胞率分别为(76.92%和41.03%),化疗后分别为(35.90%和79.49%),化疗前后差异有统计学意义(P<0.01和P=0.01)。存活时间大于3年的A、B组大肠癌患者癌组织中p27,CD44v6蛋白表达阳性细胞率分别为(90.63%和25.00%;60.00%和40.00%),存活时间小于3年的A组、B组大肠癌患者,癌组织中p27,CD44v6蛋白表达阳性细胞率分别为(42.86%和71.43%;24.14%和82.76%),A,B两组不同生存期患者大肠癌组织CD44v6,p27蛋白表达差异均有统计学意义(分别为P<0.05,P=0.01,P<0.01和P<0.05);新辅助化疗2周期后大肠癌患者血红蛋白减少发生率为10.26%(8/78),白细胞减少发生率为20.51%(16/78),血小板减少发生率为3.85%(3/78),恶心、呕吐发生率为32.04%(25/78),腹泻发生率为25.64%(20/78),但均未发生>III级的不良反应。结论:新辅助化疗有利于中晚期大肠癌患者的治疗,耐受性好;CD44v6,p27的联合检测有助于判断大肠癌患者的预后。Objective： To investigate the influence of new neoadjuvant chemotherapy on the prognosis and the protein expression of CD44v6 and p27 in patients with colorectal cancinoma. Methods ： Totally 78 patients with colorectal cancinoma underwent surgery were enrolled from January 2007 to January 2010, including 39 males and 39 females. We divided patients into group A （I, IIA, n=39） and group B （IIB, III, IV, n=39） according to clinical stages. Immunohistochemistry was performed to detect the expression of CD44v6 and p27 before and after neoadjuvant chemotherapy. The side effects after neoadjuvant chemotherapy were recorded according to Common Terminology Criteria for Adverse Events, edition 3 （CTCAE3）. Results： Expression of CD44v6 and p27 in patients of group A had no statistically significant difference before and after neoadjuvant chemotherapy （P 〉 0.05）. Positive expression ratios of CD44v6 and p27 in patients of group B were 76.92% and 41.03% before neoadjuvant chemotherapy, and 35.09% and 79.49% after neoadjuvant chemotherapy. There was significant difference before and after neoadjuvant chemotherapy （P 〈 0.01 ）. Positive expression ratios of CD44v6 and p27 i,J patients with surviving time over 3 years in group A and B were 90.63% , 25.00% and 60.00% , 40.00% , respectively. Positve expression ratios of CD44v6 and p27 in patients with surviving time less than 3 years in group A and B were 42.86% , 71.43% and 24.14% 和 82.76% , respectively. The differences between two groups were statistically significant （P 〈0.05 and P 〈0.01 ）. The （8/78）, 20.51% （16/78） and 3.85% 25.64% （20/78） , respectively, after 2 incidences of reduction in hemoglo （3/78） , and those of nausea and leucocytes, platlets diarrhea were 32 cycle neoadjuvant chemotherapy. No side effects 04% over were 10. 26% （25/78） and III grade were found. Conclusion： Neoadjuvant chemotherapy has a satisfactory effect and mild side effects for moderate and advanced colorectal carcinoma. The detecti

关 键 词：大肠癌 新辅助化疗 CD44V6 P27 预后 

分 类 号：R730.45[医药卫生—肿瘤] R735.35[医药卫生—临床医学]